

PATENT Attorney Reference No. 4239-61541

RECEIVED

NOV 0 8 2002

TECH CENTER 1600/200

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Pastan et al.

Application No. 09/763,393

Filed: July 30, 2001

For: PAGE-4, AN X-LINKED GAGE-LIKE GENE

EXPRESSED IN NORMAL AND

NEOPLASTIC PROSTATE, TESTIS AND

UTERUS, AND USES THEREFOR

Examiner: To be assigned

Date: October 30, 2002

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on October 30, 2002, as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON D.C. 20231.

Susan Alpert Siegel, Ph.D.

Agent for Applicant

Art Unit: 1646

TRANSMITTAL LETTER

COMMISSIONER FOR PATENTS WASHINGTON, DC 20231

Enclosed for filing in the application referenced above are the following:

✓ Information Disclosure Statement✓ Form 1449 and references cited thereon

The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.

Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, ZDP

By

Susan Alpert Siegel, Ph.D. Registration No. 43,121


One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

cc:

Docketing



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Pastan et al.

Application No. 09/763,393

Filed: July 30, 2001

For: PAGE-4, AN X-LINKED GAGE-LIKE GENE EXPRESSED IN NORMAL AND NEOPLASTIC PROSTATE, TESTIS AND

UTERUS, AND USES THEREFOR

Examiner: To be assigned

Date: October 30, 2002

Art Unit: 1646

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on October 30, 2002 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON,

D.C. 20231

Susan Alpert Siegel, Ph.D. Agent for Applicant

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

RECEIVED

NOV 0 8 2002

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS WASHINGTON, DC 20231

Sir:

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS.

However, if the Patent Office determines that a fee is required for Applicants to file this Information Disclosure Statement, please charge any such fees, or credit overpayment, to Deposit

Account No. 02-4550. A duplicate copy of this Information Disclosure Statement is enclosed.

Respectfully submitted,


KLARQUIST SPARKMAN, LLP

By

Susan Alpert Siegel, Ph.D. Registration No. 43,121

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 226-7391

Facsimile: (503) 228-9446



Docket: 4239-61541

App: 09/763,393

Applicant: Pastan et al.

Filed: July 30, 2001

Art Unit:

ATENT		U.S. PA	TENT DOCUMENTS		TE	CH CENTE		
Init.*	Number	Date	Name	Class	Sub	Filed		
	5,662,907	9/2/97	Kubo et al.					
		ОТН	ER DOCUMENTS					
	expres.	Brinkmann, U. et al., PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus, Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 10757-10762, (September 1998).						
		Buus, S., Description and prediction of peptide-MHC binding: the 'human MHC project', Curr. Opin. Immun., 11: 209-213 (1999). Celis, E. et al., Epitope selection and development of peptide based vaccines to treat cancer, Cancer Biology, Vol. 6, pp. 329-336 (1995).						
	· · · · · · · · · · · · · · · · · · ·							
	primar	Celis, E. et al., Induction of anti-tumor cytotoxic lymphocytes in normal humans usi primary cultures and synthetic peptide epitopes, Proc. Natl. Acad. Sci. USA, V 91, pp. 2105-2109, (March 1994).						
	Mage-		ion of Potential CTL Epitopes of nmon HLA-A Alleles, Molecula 1994).					
	Immun The Su	otherapeutics bunit and Adj	I Testing of Peptide-Based Cyto to Treat Infectious Diseases are uvant Approach, Chapter 38, e ew York (1995).	nd Cancer,	Vaccine	Design:		
			Complementary Methods for Probility Complex Molecules, J. M					
		ia, A., <i>Identify</i> 7-944, (May 1	ving Strategies for Immune Inte 4, 1999).	rvention, S	cience, V	ol. 260,		
	• • • • • • • • • • • • • • • • • • •	e, H. et al., <i>MH</i> -228, (1995).	IC ligands and peptide motifs:	first listing	, Immuno	ogentics,		

S	AS:smm	10/30/200	2 4239-6	51541 110506.doc				
	i joba popularion proci ocume			TON DICCI OCUDE	Docket: 4239-61541	App: 09/763,393		
	. 6	IN ORMATION DISCLOSURE STATEMENT			Applicant: Pastan et al.			
	May 0	T. W.	BY A	APPLICANT	Filed: July 30, 2001	Art Unit:		
	AIL			Schafer, J. et al., Predictio algorithm, EpiMatrix	•			
				Sidney et al., Broadly Reactive HLA Restricted T Cell Epitopes and Their Implicate for Vaccine Design, Concepts in Vaccine Development, Chapter 2, Ed. Kaufmann, S., Walter de Gryter, Berlin, New York (1996).				
			1	Sinigaglia, F. and Hammer, J., Motifs and Supermotifs for MHC Class II Binding Peptides, J. Exp. Med., Vol. 181, pp. 449-451, (February 1995).				
					very of three genes specifically expressed in human prostate e tag database analysis, Proc. Natl. Acad. Sci. USA, Vol. ary 1998).			
ŀ								

Eur. J. Immunol., 27:671-678, (1997).

EXAMINER:

not in conformance and not considered. Send copy.

Vitiello, A. et al., Comparison of cytotoxic T lymphocyte responses induced by peptide or DNA immunization: implications on immunogenicity and immunodominance,

DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if

RECEIVED

NOV 0 8 2002

TECH CENTER 1600/2900